-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KDZPUjj/s1BhpgETC1Mmoi5pq9TcPYRqn+4bwtpmb/EB6HXQkJg8+39odrgsK7Y7
 3SFOe/xkgutPHaHhSLca+A==

<SEC-DOCUMENT>0000012208-08-000014.txt : 20080506
<SEC-HEADER>0000012208-08-000014.hdr.sgml : 20080506
<ACCEPTANCE-DATETIME>20080506163624
ACCESSION NUMBER:		0000012208-08-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080506
DATE AS OF CHANGE:		20080506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		08806809

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8kcoverq03312008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="04/21/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: May 6, 2008</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Commission File Number: 1-7928</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=562.733><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=565.6><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=616.267><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=615><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=285.933></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=285.933><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">On May 6, 2008, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the quarter ended March 31, 2008. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated May 6, 2008</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">May 6, 2008</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="margin:0px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Christine A. Tsingos<U> </U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Exhibit</B></P>
<P style="line-height:12px; margin:0px; font-size:9.333px"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:9.333px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated May 6, 2008</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99103312008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="04/21/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px" align=right><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="line-height:14.667px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:12px"><FONT FACE="Arial"><B><I>FOR IMMEDIATE RELEASE</I></B></FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:20px; margin:0px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD REPORTS FIRST-QUARTER SALES INCREASE 31% </B></FONT></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>HERCULES, CA &#150; May 6, 2008 &#150;</B> Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced financial results today for the first quarter ended March 31, 2008. &nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">First-quarter revenues were $422.2 million, up 30.9% compared to $322.5 million reported for the first quarter of 2007. On a currency-neutral basis, revenues increased<FONT COLOR=#0000FF> </FONT>23.9% compared to the same period last year. These results were driven by continued growth across product areas in both the Life Science and Clinical Diagnostics segments as well as the addition of DiaMed Holding AG products to the Company&#146;s portfolio in the fourth quarter of 2007, which contributed additional revenue of $62.7 million. Excluding the additional revenue from the DiaMed acquisition, first-quarter revenues were up 11.5%, or 4.5% on a currency-neutral basis, compared to the same quarter in 2007. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Net income for the first quarter was $26.5 million, or $0.96 per share on a fully diluted basis, compared to $27.0 million, or $0.99 per share, respectively,<FONT COLOR=#0000FF> </FONT>during the same period last year. Reflected in operating income are $6.7 million of amortization and purchase accounting adjustments associated with the DiaMed acquisition. First-quarter gross margin was 53.7% compared to 55.6% in the first quarter last year. The lower margin in the first quarter reflects the impact of the DiaMed acquisition including foregone profit margin and the amortization of intangibles.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">&#147;Financial results for the first-quarter reflect continued strength in many of our product areas,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;As the year progresses, we will continue to focus on the integration of DiaMed and expect to begin realizing the full potential of the combined businesses in the next several quarters.&#148;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<A NAME="OLE_LINK1"></A><A NAME="OLE_LINK2"></A><P style="line-height:22.667px; margin:0px; font-family:HelveticaNeueLT Std"><B>Life Science </B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Life Science segment net sales for the quarter were<FONT COLOR=#0000FF> </FONT>$154.6 million, up 9.2% compared to the same period last year. On a currency-neutral basis, segment sales increased by 2.3%.<FONT COLOR=#0000FF> </FONT>Performance in this segment benefited<FONT COLOR=#0000FF> </FONT>from sales of its electrophoresis products as well as Bio-Plex<SUP>&#174;</SUP> suspension array system reagents, as several new assay panels were introduced during the quarter that fueled growth of this product line. During the quarter, the segment began shipping its next generation polymerase chain reaction (PCR) instruments, the new 1000-series thermal cycling and CFX Real Time platforms. Capital instrument sales for the Life Science segment were down slightly during the quarter, reflecting a general </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><P style="padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports First-Quarter Sales Increase 31%</I></B></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std"><B><I>Page 2</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">softness in the market resulting from reduced spending by both academic and bio-pharmaceutical customers. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:22.667px; margin:0px; font-family:HelveticaNeueLT Std"><B>Clinical Diagnostics</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">The Clinical Diagnostics segment reported net sales of $263.7 million for the first quarter, up 48.4% </P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">compared to the first quarter last year, or 41.3% excluding currency effects. Excluding revenue from the DiaMed acquisition,<FONT COLOR=#FF0000> </FONT>net sales were up 13.1%, or 6.0% on a currency-neutral basis, from the same period last year. These results were largely due to growth across all product lines most notably diabetes, microbiology, virology, and quality control products, as well as additional revenue resulting from the acquisition of DiaMed in October 2007, which contributed instruments and reagents used in blood typing and screening to the Company&#146;s product offerings. During the quarter, the MRSA<I>Select</I><SUP>TM</SUP> test, a chromogenic medium used for the rapid screening of MRSA (methicillin-resistant <I>Staphylococcus aureus</I>), continued to gain market acceptance in the U.S. along with the in2it<SUP>TM</SUP> analyzer for point-of-care hemoglobin A1C testing, which was introduced in the fourth quarter o
f 2007. During the quarter, the segment introduced the BioPlex<SUP>&#174;</SUP> 2200 Vasculitis kit for use on the BioPlex<SUP>&#174;</SUP> 2200 system, which employs multiplexing technology to analyze multiple disease markers from a single patient sample.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>&nbsp;</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) May 6, 2008. Interested parties can access the call by dialing 800-599-9829 (in the U.S.), or 617-847-8703 (international), access number 53867766. The live webcast can be accessed at http://www. bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 44990505, for seven days following the call and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>About Bio-Rad </B><FONT COLOR=#0000FF>&nbsp;</FONT></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by </I></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><P style="padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports First-Quarter Sales Increase 31%</I></B></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std"><B><I>Page 3</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><I>the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements</I>. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>For more information contact:</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">investor_relations@bio-rad.com<FONT FACE="Courier New"> </FONT></P>
<P style="margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std"><B><I>&nbsp;</I></B></P>
<P style="margin:0px"><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=392.8></TD><TD width=12></TD><TD width=84></TD><TD width=24></TD><TD width=96></TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px"><FONT FACE="Times New Roman">PART 1 &#150; FINANCIAL INFORMATION</FONT></P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px">Item 1. &nbsp;Financial Statements.</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=204 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=204 colspan=3><P style="margin:0px" align=center>Three Months Ended</P>
</TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=204 colspan=3><P style="margin:0px" align=center>March 31,</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin:0px" align=center>2008</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin:0px" align=center>2007</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px">Net sales</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;422,197&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;322,508&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Cost of goods sold</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="margin:0px" align=right>195,314&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>143,127&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Gross profit</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>226,883&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>179,381&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px">Selling, general and administrative expense</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>139,655&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>107,750&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Product research and development expense</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>37,489&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>32,781&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Interest expense</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>7,957&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>7,869&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Foreign exchange (gains) losses, net</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>2,593&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>(272)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Other (income) expense, net</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="margin:0px" align=right>(193)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(6,186)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Income before taxes<B> </B>and minority interests</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>39,382&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>37,439&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px">Provision for income <B>t</B>axes</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="margin:0px" align=right>(10,823)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>(10,442)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Minority interests in earnings of consolidated subsidiaries</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="margin:0px" align=right>(2,064)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Net income</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26,495&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26,997&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px">Basic earnings per share:</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Net income</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="margin:0px" align=right>$ &nbsp;0.99&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;1.02&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Weighted average common shares</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="margin:0px" align=right>26,881&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>26,580&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px">Diluted earnings per share:</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Net income</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="margin:0px" align=right>$ &nbsp;0.96&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;0.99&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Weighted average common shares</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="margin:0px" align=right>27,464&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>27,156&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=608.8 colspan=5><P style="margin:0px">The accompanying notes are an integral part of these condensed consolidated financial statements.</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=right><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; padding-left:-48px; padding-right:-65.333px; font-size:12px; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0px; font-size:12px" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0px; font-size:12px" align=center>(In thousands)</P>
<P style="margin:0px; font-size:12px" align=center>(Unaudited)</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=423.933></TD><TD width=17></TD><TD width=80.867></TD><TD width=17></TD><TD width=92.867></TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="margin:0px; font-size:12px" align=center>March 31,</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="margin:0px; font-size:12px" align=right>December 31,&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=80.867><P style="margin:0px; font-size:12px" align=center>2008</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=92.867><P style="margin:0px; font-size:12px" align=center>2007</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Current assets: </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Cash and cash equivalents</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;129,480&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;161,764&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Short-term investments</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>47,643&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>61,977&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts receivable, net </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>366,509&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>358,076&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Inventories, net </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>365,059&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>321,015&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current assets</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=80.867><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>140,340&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>126,142&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current assets </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>1,049,031&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>1,028,974&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Net property, plant and equipment </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>287,573&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>271,561&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Goodwill </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>352,671&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>328,439&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Purchased intangibles, net</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>232,614&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>210,304&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Other assets </P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=80.867><P style="margin:0px; font-size:12px" align=right>131,399&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>132,316&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; text-indent:28.8px; font-size:12px">Total assets</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=80.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,053,288&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,971,594&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Current liabilities:</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15,677&nbsp;</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15,627&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts payable</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>98,929&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>96,470&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>96,836&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>121,255&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Sales, income and other taxes payable</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>36,832&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>27,905&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current liabilities</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=80.867><P style="margin:0px; font-size:12px" align=right>139,172&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>152,911&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current liabilities</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>387,446&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>414,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>442,446&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>441,805&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Other long-term liabilities</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>110,880&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>109,497&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Minority interests</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=80.867><P style="margin:0px; font-size:12px" align=right>30,249&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=92.867><P style="margin:0px; font-size:12px" align=right>34,434&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; font-size:12px">Stockholders&#146; equity</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=80.867><P style="margin:0px; font-size:12px" align=right>1,082,267&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>971,690&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="margin:0px; text-indent:38.4px; font-size:12px">Total liabilities, minority interests and stockholders&#146; equity</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=80.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,053,288&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=92.867><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1 ,971,594&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=423.933><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=80.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=92.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:14.667px; margin-top:0px; margin-bottom:6px; font-size:12px">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=427.667></TD><TD width=72></TD><TD width=24></TD><TD width=72></TD></TR>
<TR><TD valign=top width=595.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=595.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=595.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=595.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=168 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=168 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Three Months Ended</P>
</TD></TR>
<TR><TD valign=top width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=168 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>March 31,</P>
</TD></TR>
<TR><TD valign=top width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=72><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2008</P>
</TD><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=72><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2007</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from operating activities:</P>
</TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash received from customers</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;436,521&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;327,214&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash paid to suppliers and employees</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(421,973)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(324,067)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Interest paid</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(8,938)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(8,540)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Income tax payments</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(6,398)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(12,424)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,098)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,033)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other operating activities</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(291)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>6,209&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash used in operating activities</P>
</TD><TD style="border-top:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(2,177)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(12,641)</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from investing activities:</P>
</TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Payments for acquisitions and long-term investments</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,106)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(860)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other investing activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,858)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>12,718&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by (used in) investing activities</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(34,964)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>11,858&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from financing activities:</P>
</TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Payments on long-term debt</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(2,190)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(123)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other financing activities</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>4,979&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>7,388&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Net cash provided by financing activities</P>
</TD><TD style="border-top:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>2,789&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>7,265&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Effect of exchange rate changes on cash</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>2,068&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>225&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net increase (decrease) in cash and cash equivalents</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(32,284)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>6,707&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>161,764&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>223,607&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2.667px double #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;129,480&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;230,314&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin:0px; padding-left:19.2px; font-size:12px">Reconciliation of net income to net cash used in operating activities:</P>
</TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin:0px; padding-left:19.2px; font-size:12px">Net income </P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26,495&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26,997&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Adjustments to reconcile net income to net cash used in operating activities:&nbsp;</P>
</TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Depreciation and amortization</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>23,740&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>14,375&nbsp;</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Changes in working capital</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(60,027)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(51,579)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,098)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,033)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other</P>
</TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>8,713&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,401)</P>
</TD></TR>
<TR><TD width=427.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net cash used in operating activities</P>
</TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2,177)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=72><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12,641)</P>
</TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=427.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=72><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
